A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults

BACKGROUND: This first in human study was designed as an open label clinical trial to assess safety and tolerability of Serum Institute of India Pvt. Ltd. (SIIPL) quadrivalent HPV (qHPV) vaccine. METHODS: A total of 48 healthy male and female (24 each) adult volunteers were administered a 0.5 ml sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Hitt, Anil, K., Parekh, Sameer, Pujari, Pramod, Shewale, Sunil, Desai, Shivani, Madhusudhan, R.L., Patel, Jaya, Eswaraiah, Anand, Rao, Harish, Gairola, Sunil, Shaligram, Umesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205786/
https://www.ncbi.nlm.nih.gov/pubmed/37234594
http://dx.doi.org/10.1016/j.jvacx.2023.100313
Descripción
Sumario:BACKGROUND: This first in human study was designed as an open label clinical trial to assess safety and tolerability of Serum Institute of India Pvt. Ltd. (SIIPL) quadrivalent HPV (qHPV) vaccine. METHODS: A total of 48 healthy male and female (24 each) adult volunteers were administered a 0.5 ml single dose of SIIPL qHPV vaccine intramuscularly, and were followed for one month for safety outcomes viz., immediate, solicited, unsolicited and serious adverse events. RESULTS: 47 subjects completed the study in compliance with protocol. One subject had pain immediately after immunization which was recovered without treatment. None of the participants experienced any other local or systemic solicited AEs and serious AE. CONCLUSION: qHPV vaccine manufactured by SIIPL was found to be safe and well tolerable in adults. Further clinical development should continue to assess safety and immunogenicity, in the target population following recommended 2 and 3-dose schedule. Clinical Trial Registration – CTRI/2017/02/007785.

Ejemplares similares